
Axsome Therapeutics doses first pediatric adhd trial patient
- Axsome Therapeutics (NASDAQ:AXSM) dosed the first patient in its Phase 3 FOCUS-2 clinical trial evaluating solriamfetol in children with attention deficit hyperactivity disorder.
- The initiation of active pediatric testing broadens the clinical development pipeline for the central nervous system drug candidate.
- Axsome plans to leverage the study's safety and efficacy data to complement its ongoing adolescent trial and expand into the pediatric market.
Axsome Therapeutics (NASDAQ:AXSM) announced it dosed the first patient in its Phase 3 FOCUS-2 clinical trial evaluating solriamfetol as a potential treatment for children with attention deficit hyperactivity disorder.
The newly initiated trial expands the biopharmaceutical firm's active pediatric pipeline following the recent deployment of its companion FOCUS-3 study targeting adolescent patients.
"The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD," stated the central nervous system specialist in its clinical trial initialization bulletin.
The multi-center study will randomize its entire patient registry under a strict one-to-one-to-one ratio to receive one of two distinct active drug doses or a matching placebo.
The randomized, double-blind, placebo-controlled protocol evaluates the investigational dopamine and norepinephrine reuptake inhibitor over a fixed six-week treatment period.
The clinical investigators will track changes from baseline in the standardized ADHD Rating Scale total score as the study's primary efficacy endpoint.
More from United States
C3is reports $1.2 million Q3 net loss as revenue rises
Cosmos Health revenue hits $53.6 million, up 17.6%
Summit launches Phase III lung cancer trial for ivonescimab
DataMeds AI issues 630,000 shares in cancer partnership
CoinShares net income improves 27% to $39.6 million
newcleo revenue skyrockets 26% to €10 million in Q3